NXTM - Nxstage Medical, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
25.41
-0.45 (-1.74%)
At close: 4:00PM EDT

25.41 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close25.86
Open25.87
Bid25.37 x 2000
Ask29.94 x 300
Day's Range25.38 - 25.87
52 Week Range20.45 - 30.80
Volume274,345
Avg. Volume615,467
Market Cap1.685B
Beta0.24
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about NxStage Medical Inc.
    Markit3 days ago

    See what the IHS Markit Score report has to say about NxStage Medical Inc.

    NxStage Medical Inc NASDAQ/NGS:NXTM

  • See what the IHS Markit Score report has to say about NxStage Medical Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about NxStage Medical Inc.

    NxStage Medical Inc NASDAQ/NGS:NXTM

  • Why Abiomed’s Product Pipeline Looks Promising
    Market Realist2 months ago

    Why Abiomed’s Product Pipeline Looks Promising

    Abiomed (ABMD) is strategically focused on the market penetration of the company’s family of Impella heart pumps. The Impella device portfolio consists of Impella 2.5, Impella CP, Impella RP, Impella LD, and Impella 5.0 devices. To this end, Abiomed discontinued the sale of its AB5000 device used for heart surgery.

  • What Analysts Recommend for Abiomed and Peers in February 2018
    Market Realist2 months ago

    What Analysts Recommend for Abiomed and Peers in February 2018

    Abiomed (ABMD) is a supplier of mechanical circulatory support devices and offers a continuum of care to heart failure patients. Abiomed develops, manufactures, and commercializes products designed to improve the blood flow and perform the pumping function of the heart. Of the ten analysts covering Abiomed (ABMD) in February 2018, five analysts have given the stock a “strong buy” rating, three analysts have given it a “buy” rating, while two analysts have given it a “hold” rating.

  • Wider Losses Worry NxStage Medical Shareholders
    Motley Fool2 months ago

    Wider Losses Worry NxStage Medical Shareholders

    An increasing discount to the buyout price for the dialysis specialist's stock is raising concerns.

  • A Look at NxStage Medical’s Business Strategy
    Market Realist2 months ago

    A Look at NxStage Medical’s Business Strategy

    At present, in-center hemodialysis is the predominant ESRD (end stage renal disease) therapy in the United States. According to NxStage Medical (NXTM), ~10%–15% of ESRD patients in the United States would be appropriate candidates for the company’s home dialysis equipment, System One. According to Centers for Medicare and Medicaid (or CMS), only 18% of dialysis clinics in the United States actively offer home hemodialysis for patients, and only 27% are certified to offer this therapy.

  • Insight into the NxStage Medical–Fresenius Medical Care Merger
    Market Realist2 months ago

    Insight into the NxStage Medical–Fresenius Medical Care Merger

    Since its inception, NxStage Medical (NXTM) has focused on creating a long-term sustainable model driven by innovative technologies. Although NxStage Medical has witnessed revenue growth, it has historically operated at a net loss. It expects the operating income it generates from its products business to continue to be offset by the losses in its kidney care business and the costs associated with its merger with Fresenius Medical Care Holdings (FAS).

  • Analysts’ Ratings for NxStage Medical and Peers in February 2018
    Market Realist2 months ago

    Analysts’ Ratings for NxStage Medical and Peers in February 2018

    Headquartered in Lawrence, Massachusetts, NxStage Medical (NXTM) is a medical technology company with a focus on developing, manufacturing, and marketing innovative products targeted at patients suffering from chronic or acute kidney failure. The company also operates NxStage kidney care dialysis centers, which treat end-stage renal disease (or ESRD) patients. NxStage Medical’s primary product is System One, which is capable of delivering the therapeutic flexibility and clinical benefits of traditional dialysis machines in a smaller, portable, and easy-to-use format.

  • Barrons.com2 months ago

    [$$] Big Stock Buys: Bluebird, Walgreens, Mallinckrodt

    Hedge fund Deerfield Management was fresh off a settlement with the Securities and Exchange Commission as the fourth quarter began. As the fourth quarter played out, Deerfield got back to making investment moves in health care and biotech. Deerfield initiated positions in Walgreens Boots Alliance (WBA) and Bluebird Bio (BLUE), more than tripled its holdings in Mallinckrodt (MNK), sold a fifth of its Mylan (MYL) investment, and exited NxStage Medical (NXTM) altogether.

  • See what the IHS Markit Score report has to say about NxStage Medical Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about NxStage Medical Inc.

    NxStage Medical Inc NASDAQ/NGS:NXTM

  • NxStage Medical, Inc. :NXTM-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
    Capital Cube4 months ago

    NxStage Medical, Inc. :NXTM-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017

    Categories: Yahoo FinanceGet free summary analysis NxStage Medical, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of NxStage Medical, Inc. – Rockwell Medical, Inc., Fresenius Medical Care AG & Co. KGaA Sponsored ADR, Cantel Medical Corp., C. R. Bard, Inc., Baxter International Inc., Nephros, Inc., ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about NxStage Medical Inc.
    Markit4 months ago

    See what the IHS Markit Score report has to say about NxStage Medical Inc.

    NxStage Medical Inc NASDAQ/NGS:NXTM

  • NxStage Nx2me Connected Health Improves Home Hemodialysis
    Zacks4 months ago

    NxStage Nx2me Connected Health Improves Home Hemodialysis

    NxStage Medical (NXTM) consistently looks to expand dialysis platform.

  • See what the IHS Markit Score report has to say about NxStage Medical Inc.
    Markit5 months ago

    See what the IHS Markit Score report has to say about NxStage Medical Inc.

    NxStage Medical Inc NASDAQ/NGS:NXTM

  • See what the IHS Markit Score report has to say about NxStage Medical Inc.
    Markit5 months ago

    See what the IHS Markit Score report has to say about NxStage Medical Inc.

    NxStage Medical Inc NASDAQ/NGS:NXTM

  • Reuters5 months ago

    Prospect of tougher antitrust regulation worries deal investors

    The top U.S. antitrust regulator has sent a chilling message to dealmakers with his opposition to AT&T Inc buying Time Warner Inc: Companies do not have to be competitors for their merger to hurt competition, and there are no simple fixes to get such deals approved. The Department of Justice's lawsuit to block the AT&T purchase could be a negative sign for other so-called "vertical" mergers - where the companies do not compete but one supplies the other - such as pharmacy operator CVS Health Corp's plan to buy insurer Aetna Inc. Investors had thought AT&T's acquisition of Time Warner, if not a slam dunk, would be approved by the Justice Department and its antitrust division chief Makan Delrahim with relatively few asset sales or conditions.

  • NxStage Medical Prepares for Fresenius Merger
    Motley Fool5 months ago

    NxStage Medical Prepares for Fresenius Merger

    Find out how the dialysis specialist's business fared in the shadow of a buyout bid.

  • Capital Cube6 months ago

    ETFs with exposure to NxStage Medical, Inc. : October 23, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to NxStage Medical, Inc. Here are 5 ETFs with the largest exposure to NXTM-US. Comparing the performance and risk of NxStage Medical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about NxStage Medical Inc.
    Markit6 months ago

    See what the IHS Markit Score report has to say about NxStage Medical Inc.

    NxStage Medical Inc NASDAQ/NGS:NXTM

  • NxStage Medical, Inc. breached its 50 day moving average in a Bullish Manner : NXTM-US : October 6, 2017
    Capital Cube6 months ago

    NxStage Medical, Inc. breached its 50 day moving average in a Bullish Manner : NXTM-US : October 6, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for NxStage Medical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about NxStage Medical Inc.
    Markit7 months ago

    See what the IHS Markit Score report has to say about NxStage Medical Inc.

    NxStage Medical Inc NASDAQ/NGS:NXTM